Skip to content

Efficacy and mechanisms of imagery rescripting and imaginal exposure for nightmares: study protocol for a randomized controlled trial.

Anna E Kunze, Jaap Lancee, Nexhmedin Morina, Merel Kindt, Arnoud Arntz

Trials September 26, 2016 DOI: 10.1186/s13063-016-1570-3 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial (study protocol) Peer reviewed
Sample size 90
Population Adults suffering from nightmare disorder
Interventions Imagery rescripting (IR) Imaginal exposure (IE)
Duration Three weekly sessions; follow-up assessments at 3 and 6 months after post-assessment
Topics Dreaming
Keywords Rct Imagery rehearsal therapy Nightmare disorder Imaginal exposure Imagery rescripting Idiopathic nightmares Posttraumatic nightmares
Key findings The protocol outlines a randomized controlled trial designed to test the efficacy of stripped-down imagery rescripting and imaginal exposure treatments for nightmare disorder against a waiting-list control, and to explore proposed mediators of their therapeutic effects. The authors propose that identifying these mechanisms may advance understanding of psychological treatments for chronic nightmares and, more broadly, of rescripting-based and exposure-based therapies.

Abstract

Background: Recurrent nightmares can effectively be treated with cognitive-behavioral techniques such as imagery rehearsal therapy, which involves imagery rescripting (IR) of nightmares, and imaginal exposure (IE) therapy. However, the underlying mechanisms of these treatments remain largely unknown. To investigate this, we identified a number of variables that might mediate the therapeutic effect of rescripting-based and/or exposure-based therapies. Also, to control for the possible confounding influence of (other) treatment components, we designed two stripped-down treatment protocols, which primarily consist of either (1) rescripting of, or (2) exposure to, the nightmare content. In a randomized controlled trial, we aim to investigate the therapeutic efficacy of these stripped-down IR and IE treatments, and explore their working mechanisms.

Method: Three weekly sessions of either IR or IE will be compared to a waiting-list control group. Ninety participants suffering from nightmare disorder will be included and randomly allocated to one of the three groups. The primary clinical outcome measures are nightmare frequency and distress caused by nightmares. Secondary clinical outcome measures include sleep complaints, dysfunctional beliefs about nightmares, and posttraumatic stress symptom severity. Outcomes will be assessed weekly from week 1 (pre-assessment) to week 5 (post-assessment). Online follow-up assessments will take place at 3 and 6 months after post-assessment. In order to investigate temporal relationships between mediators and outcome, we will measure the proposed mediators of the treatment effect 1 day after each outcome assessment (but not after the follow-ups). Mediators include nightmare distress and valence, mastery of the nightmare content, predictability, controllability, and tolerability of emotions elicited by nightmares, as well as sleep quality.

Discussion: The proposed trial allows us to investigate the efficacy of IR and IE as intervention techniques for the treatment of nightmares, and to explore mediators of their respective therapeutic effects. The results may advance our understanding of nightmare therapies by identifying possible mechanisms of psychological treatments for chronic nightmares. Moreover, the results of the proposed study might provide useful knowledge about the working mechanism of rescripting-based and exposure-based treatments in general.

Trial Registration: Netherlands Trial Register ( NTR4951 ), registered on 14 December 2014.

Comparable studies

Other randomized controlled trials on dreaming, most cited first.

Study Year Design Participants
Efficacy of a Cognitive‐Behavioral Treatment for Insomnia and Nightmares in Afghanistan and Iraq Veterans With PTSD Combat veterans of Operation Enduring Freedom and/or Operation Iraqi Freedom (mean age... 2013 Randomized controlled trial n = 40
Lucid Dreaming Treatment for Nightmares: A Pilot Study Chronic nightmare sufferers 2006 Randomized controlled trial n = 23
Testing the involvement of the prefrontal cortex in lucid dreaming: A tDCS study Participants spending three consecutive nights in a sleep laboratory 2013 Randomized controlled trial n = 19
Pre-sleep treatment with galantamine stimulates lucid dreaming: A double-blind, placebo-controlled, crossover study Adults with high dream recall and an interest in lucid dreaming 2018 Randomized crossover trial n = 121
Studies with lucid dreaming as add-on therapy to Gestalt therapy Adults with nightmares (ICD-10: F51.5) at least twice a week 2015 Randomized controlled trial n = 32

Citations in the library

Explore topics